Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Clinical trial NCT05110742 · RECRUITING
Trial details
- NCT number
- NCT05110742
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-22
- Primary completion
- 2030-12-31
- Enrollment
- 64
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.